Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31456
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-03-09T07:50:44Z-
dc.date.available2023-03-09T07:50:44Z-
dc.date.issued2007-07-30-
dc.identifier.citationAkkaya, C. vd. (2007). "Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting". Human Psychopharmacology, 22(8), 515-528.en_US
dc.identifier.issn0885-6222-
dc.identifier.issn1099-1077-
dc.identifier.urihttps://doi.org/10.1002/hup.882-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/hup.882-
dc.identifier.urihttp://hdl.handle.net/11452/31456-
dc.description.abstractObjective To report the outcomes of a retrospective database analysis to compare the effectiveness of atypical and typical antipsychotic drugs. Methods Medical records of patients admitted to the psychiatry outpatient clinic between January 1998 and October 2005 were retrospectively reviewed. Data obtained from patient records were noted on a special form assessing four aspects of the treatment history: socio-demographic features, disease characteristics, initial treatment at the time of admission, and course of treatment. Patient groups (typical/atypical and Risperidone/Haloperidol/Olanzapine) were compared for time to all-cause medication discontinuation and rate of discontinuation. Results There was no statistically significant difference in the duration of treatment between patients using atypical (n=150) and typical (n=124) antipsychotics. The duration of treatment was significantly longer in patients on Haloperidol (n=91) compared with those on Risperidone (n=63). Rates of discontinuation over 18 months were 59.3% for patients on atypical antipsychotics and 57.3% for those on typical antipsychotics, and 68.3% for patients on Risperidone, 51.6% for patients on Haloperidol and 54.3% for patients on Olanzapine. Conclusion Despite our hypothesis patients with chronic schizophrenia discontinued their atypical and typical antipsychotics, at a high rate with no significant difference indicating substantial limitations in the effectiveness of these drugs.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSchizophreniaen_US
dc.subjectDatabase analysisen_US
dc.subjectAntipsychotic treatmenten_US
dc.subjectEffectivenessen_US
dc.subjectNew-generation antipsychoticsen_US
dc.subjectControlled-trialsen_US
dc.subject2nd-generation antipsychoticsen_US
dc.subjectRehospitalization ratesen_US
dc.subjectChronic-schizophreniarandomized-trialsen_US
dc.subjectMedicationen_US
dc.subjectCatieen_US
dc.subjectMetaanalysisen_US
dc.subjectTherapyen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subjectPsychologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAntipsychotic agentsen_US
dc.subject.meshBenzodiazepinesen_US
dc.subject.meshDatabases, factualen_US
dc.subject.meshFemaleen_US
dc.subject.meshHaloperidolen_US
dc.subject.meshHospitals, universityen_US
dc.subject.meshHumansen_US
dc.subject.meshLong-term careen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshOutpatient clinics, hospitalen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshRisperidoneen_US
dc.subject.meshSchizophreniaen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTreatment refusalen_US
dc.subject.meshTurkeyen_US
dc.titleRetrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic settingen_US
dc.typeArticleen_US
dc.identifier.wos000252305600003tr_TR
dc.identifier.scopus2-s2.0-37849005650tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.identifier.startpage515tr_TR
dc.identifier.endpage528tr_TR
dc.identifier.volume22tr_TR
dc.identifier.issue8tr_TR
dc.relation.journalHuman Psychopharmacologyen_US
dc.contributor.buuauthorAkkaya, Cengiz-
dc.contributor.buuauthorSarandöl, Aslı-
dc.contributor.buuauthorCangür, Şengül-
dc.contributor.buuauthorKırlı, Selçuk-
dc.identifier.pubmed17868197tr_TR
dc.subject.wosClinical neurologyen_US
dc.subject.wosPsychologyen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2 (Clinical neurology)en_US
dc.wos.quartileQ2 (Psychology)en_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid2-s2.0-37849005650tr_TR
dc.subject.scopusClozapine; Neuroleptic Agent; Schizophreniaen_US
dc.subject.emtreeAmisulprideen_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeAnxiolytic agenten_US
dc.subject.emtreeAtypical antipsychotic agenten_US
dc.subject.emtreeCarbamazepineen_US
dc.subject.emtreeChlorpromazineen_US
dc.subject.emtreeCholinergic receptor blocking agenten_US
dc.subject.emtreeClozapineen_US
dc.subject.emtreeFlupentixolen_US
dc.subject.emtreeFluphenazineen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeLithium salten_US
dc.subject.emtreeLong acting drugen_US
dc.subject.emtreeMood stabilizeren_US
dc.subject.emtreeNeuroleptic agenten_US
dc.subject.emtreeOlanzapineen_US
dc.subject.emtreePimozideen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeRisperidoneen_US
dc.subject.emtreeSulprideen_US
dc.subject.emtreeThioridazineen_US
dc.subject.emtreeTranquilizeren_US
dc.subject.emtreeTrifluoperazineen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeZuclopenthixolen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDemographyen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeExtrapyramidal syndromeen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHospital admissionen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMedical record reviewen_US
dc.subject.emtreeNausea and vomitingen_US
dc.subject.emtreeOutpatienten_US
dc.subject.emtreePatient complianceen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.emtreeSedationen_US
dc.subject.emtreeSide effecten_US
dc.subject.emtreeSocial aspecten_US
dc.subject.emtreeStatistical significanceen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeWeight gainen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.